Loading stock data…
$1166.51-16.11 (-1.36%)
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Eli Lilly and Company in the Healthcare sector is trading at $1,166.51 with a market capitalization of $1.1T. Wall Street consensus targets $1,330.14 (29 analysts), implying a +14.0% move over the next 12 months. The stock is currently 10% below its 52-week high of $1,292.65, remaining 8.5% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22.97B↑ | $19.80B↑ | $19.29B↑ | $17.60B↑ | $15.56B |
| Gross Profit | $19.71B↑ | $16.22B↑ | $15.92B↑ | $14.59B↑ | $13.11B |
| Operating Income | $12.46B↑ | $9.78B↑ | $8.99B↑ | $8.39B↑ | $7.02B |
| Net Income | $7.09B↓ | $7.40B↑ | $6.64B↑ | $5.58B↓ | $5.66B |
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humal...
Academic risk and quality models computed from LLY's own filings and price history, not from analyst opinion.
Mixed: 6 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z above the 2.99 safe threshold, so the model puts bankruptcy risk in its lowest band.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, above the current 33.2% reading.
Fama-French 5-factor market beta. The five factors explain 13% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-13.